JW (Cayman) Therapeutics Co. Ltd (2126.HK)

HKD 1.3

(0.0%)

Revenue Summary of JW (Cayman) Therapeutics Co. Ltd

  • JW (Cayman) Therapeutics Co. Ltd's latest annual revenue in 2023 was 173.85 Million CNY , up 19.32% from previous year.
  • JW (Cayman) Therapeutics Co. Ltd's latest quarterly revenue in 2024 Q2 was 86.81 Million CNY , down 0.0% from previous quarter.
  • JW (Cayman) Therapeutics Co. Ltd reported a annual revenue of 145.7 Million CNY in annual revenue 2022, up 373.1% from previous year.
  • JW (Cayman) Therapeutics Co. Ltd reported a annual revenue of 30.79 Million CNY in annual revenue 2021, down 0.0% from previous year.
  • JW (Cayman) Therapeutics Co. Ltd reported a quarterly revenue of 87.74 Million CNY for 2023 Q2, down 0.0% from previous quarter.
  • JW (Cayman) Therapeutics Co. Ltd reported a quarterly revenue of 173.85 Million CNY for 2023 FY, up 19.32% from previous quarter.

Annual Revenue Chart of JW (Cayman) Therapeutics Co. Ltd (2023 - 2018)

Historical Annual Revenue of JW (Cayman) Therapeutics Co. Ltd (2023 - 2018)

Year Revenue Revenue Growth
2023 173.85 Million CNY 19.32%
2022 145.7 Million CNY 373.1%
2021 30.79 Million CNY 0.0%
2020 - CNY -100.0%
2019 5.48 Million CNY 2450.23%
2018 215 Thousand CNY 0.0%

Peer Revenue Comparison of JW (Cayman) Therapeutics Co. Ltd

Name Revenue Revenue Difference
Uni-Bio Science Group Limited 484.71 Million HKD 64.133%
CK Life Sciences Int'l., (Holdings) Inc. 5.32 Billion HKD 96.734%